
Updated results of the MajesTEC -1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate of 62% among heavily pretreated patients with multiple myeloma.

Updated results of the MajesTEC -1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate of 62% among heavily pretreated patients with multiple myeloma.

The top 5 most-read comprehensive genomic profiling articles of 2021 on AJMC.com largely focused on the use of liquid biopsy and how biomarkers can offer providers new ways to help predict treatment-related outcomes and identify therapeutic targets.

In an interview conducted before the highly transmissible Omicron coronavirus variant began driving another wave of infections, Peter Hotez, MD, PhD, FASTMH, discussed the struggle public health officials and scientists have in fighting false beliefs about vaccinations.

People experiencing teeth grinding or clenching during sleep, called sleep bruxism, were found to be more likely than the general population to report incidence of other sleep disorders, such as obstructive sleep apnea and restless leg syndrome.

HIV specialist dieticians at this London-based charity help people with HIV by providing personalized advice on how nutrition can have a positive effect on their overall health and well-being.

Up to 500 million at-home COVID-19 test kits will be sent to US households for free, by request; Biogen cut the price of its Alzheimer disease drug Aduhelm nearly in half; the FDA approved the world’s first injectable medication to reduce the risk of sexually transmitted HIV.

This year's most-viewed content in infectious disease was dominated by COVID-19, as the Delta variant continued to strain the US health care system. It also included news about Clostridioides difficile.

Pulse pressure was found to have a significant association with chronic kidney disease (CKD), indicating that changes in pulse pressure could serve as a predictive marker for disease progression.

The top 5 most-read ophthalmology articles of 2021 on AJMC.com evaluated the effectiveness of novel therapies in several ophthalmic diseases, racial/ethnic disparities in clinical trial participation, and the impact of the COVID-19 pandemic on childhood nearsightedness.

In hopes of protecting its lucrative adalimumab (Humira) franchise, AbbVie is mounting a hefty legal defense against Alvotech's adalimumab biosimilar candidate.

Truth is ever to be found in simplicity, and not in the multiplicity and confusion of things.

Jason Myers, PhD, CEO, of the New Zealand AIDS Foundation, explains how they conducted a New Zealand version of the Stigma Index Research to solve the issue of Māori living with HIV experiencing worsened stigma and discrimination.

A new study characterizes the rate of allergic contact dermatitis among patients given skin adhesives.

A new report finds patients with systemic lupus erythematosus and 5 other autoimmune disorders face an increased risk of gastric cancers.

CDC data shown to overstate US vaccination rates; school-based cognitive behavioral therapy for overwhelmed children; Moderna to develop Omicron-specific COVID-19 booster dose.

Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center, discusses the cost of teprotumumab for thyroid eye disease.

The top 5 most-read rare disease articles of 2021 on AJMC.com highlighted research on medications, therapies, and diagnosing tools to treat myelofibrosis, hemophilia B, chronic graft-vs-host disease, necrotizing myopathy, and myeloproliferative neoplasms.

New research on semaglutide and empagliflozin appear on this year’s list of most-read diabetes articles.

Don Sin, MD, FRCP, MPH, a professor of respiratory medicine at the University of British Columbia and head of the Centre of Heart Lung Innovation, St. Paul’s Hospital, discusses future possibilities for the prevention of chronic obstructive pulmonary disease (COPD) using new biomarker discoveries and genomic technology advancements.

The top 5 most-read psoriasis articles of 2021 on AJMC.com covered risk factors involved in the pathogenesis and treatment of psoriatic disease and cost considerations for treatment.

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, describes his research on real-world treatment patterns among patients with triple-class refractory multiple myeloma.

As the pandemic wore on, fewer patients with sickle cell disease who did contract COVID-19 needed to be hospitalized.

David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine, discusses the potential therapeutic use of intranasal oxytocin spray for menstrual-related migraine.

Most people are aware of what triggers their chronic cough and how to temporarily suppress it, said Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

Under the expanded FDA label, up to 1.8 million individuals in the United States could be eligible for sacubitril/valsartan, and up to 180,000 worsening heart failure (HF) events could be prevented or postponed.

Drawing a clearer picture of the relationship between pulmonary artery involvement (PAI) in Takayasu arteritis (TAK), researchers have published data on the clinical features of TAK with PAI.

Using the fatty liver index (FLI) to identify nonalcoholic fatty liver disease (NAFLD), researchers sought to understand the association between first-degree family members of patients with diabetes and NAFLD.


Until now, researchers have not quantified the impact of regular exercise on death for any reason in patients with Parkinson disease (PD).

Adriaan Voors, MD, University Medical Center Groningen, the Netherlands, discusses how and why sodium-glucose co-transporter 2 (SGLT2) inhibitors act so quickly for patients with heart failure.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
